Last reviewed · How we verify

Symbicort® Turbohaler® Inhalation Powder

Pearl Therapeutics, Inc. · Phase 3 active Small molecule

Symbicort® Turbohaler® Inhalation Powder is a Inhaled corticosteroid/long-acting beta2-adrenergic agonist Small molecule drug developed by Pearl Therapeutics, Inc.. It is currently in Phase 3 development for Maintenance and relief of asthma symptoms, Maintenance treatment of COPD. Also known as: Symbicort.

Symbicort is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).

Symbicort is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD). Used for Maintenance and relief of asthma symptoms, Maintenance treatment of COPD.

At a glance

Generic nameSymbicort® Turbohaler® Inhalation Powder
Also known asSymbicort
SponsorPearl Therapeutics, Inc.
Drug classInhaled corticosteroid/long-acting beta2-adrenergic agonist
TargetBeta2-adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Budesonide works by reducing inflammation in the lungs, while formoterol helps to relax the airway muscles, making it easier to breathe. This combination helps to control symptoms of asthma and COPD, such as wheezing, coughing, and shortness of breath.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Symbicort® Turbohaler® Inhalation Powder

What is Symbicort® Turbohaler® Inhalation Powder?

Symbicort® Turbohaler® Inhalation Powder is a Inhaled corticosteroid/long-acting beta2-adrenergic agonist drug developed by Pearl Therapeutics, Inc., indicated for Maintenance and relief of asthma symptoms, Maintenance treatment of COPD.

How does Symbicort® Turbohaler® Inhalation Powder work?

Symbicort is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).

What is Symbicort® Turbohaler® Inhalation Powder used for?

Symbicort® Turbohaler® Inhalation Powder is indicated for Maintenance and relief of asthma symptoms, Maintenance treatment of COPD.

Who makes Symbicort® Turbohaler® Inhalation Powder?

Symbicort® Turbohaler® Inhalation Powder is developed by Pearl Therapeutics, Inc. (see full Pearl Therapeutics, Inc. pipeline at /company/pearl-therapeutics-inc).

Is Symbicort® Turbohaler® Inhalation Powder also known as anything else?

Symbicort® Turbohaler® Inhalation Powder is also known as Symbicort.

What drug class is Symbicort® Turbohaler® Inhalation Powder in?

Symbicort® Turbohaler® Inhalation Powder belongs to the Inhaled corticosteroid/long-acting beta2-adrenergic agonist class. See all Inhaled corticosteroid/long-acting beta2-adrenergic agonist drugs at /class/inhaled-corticosteroid-long-acting-beta2-adrenergic-agonist.

What development phase is Symbicort® Turbohaler® Inhalation Powder in?

Symbicort® Turbohaler® Inhalation Powder is in Phase 3.

What are the side effects of Symbicort® Turbohaler® Inhalation Powder?

Common side effects of Symbicort® Turbohaler® Inhalation Powder include Oral candidiasis, Headache, Cough, Pharyngitis, Dysphonia.

What does Symbicort® Turbohaler® Inhalation Powder target?

Symbicort® Turbohaler® Inhalation Powder targets Beta2-adrenergic receptor and is a Inhaled corticosteroid/long-acting beta2-adrenergic agonist.

Related